18F-Sodium Fluoride PET/CT in Oncology. (April 2015)

• Record Type: Journal Article
• Authors: Sabbah, Nathanael; Jackson, Tatianie; Mosci, Camila; Jamali, Mehran; Minamimoto, Ryogo; Quon, Andrew; Mittra, Erik S.; Iagaru, Andrei
• Is Part Of: Clinical nuclear medicine. Volume 40:Number 4(2015)
• Publication Date: 2015-04
• Subjects: Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000000633
• Languages: English
• ISSNs: 0363-9762

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Purpose</title> <p>The purpose of this study was to analyze the distribution of <sup>18</sup>F Sodium Fluoride (<sup>18</sup>F-NaF) uptake in the normal skeleton, benign and malignant bone lesions, and extraskeletal tissues, using semiquantitative SUV measurements.</p> </sec> <sec> <title>Patients and Methods</title> <p>We retrospectively analyzed data from 129 patients who had <sup>18</sup>F-NaF PET/CT at our institution for an oncological diagnosis between 2007 and 2014. There were 99 men and 30 women, 19 to 90 years old (mean [SD], 61.5 [15.5]). The range, average, and SD of SUV were measured for normal bone and extraskeletal tissues uptake for the entire patient population. A separate statistical analysis was performed to compare group A, which corresponds to the population of patient with no <sup>18</sup>F-NaF–avid metastatic lesions, and group B, which corresponds to the population of patient with <sup>18</sup>F-NaF–avid metastatic lesions. We also measured SUVmax and SUVmean for bony metastases and degenerative changes</p> </sec> <sec> <title>Results</title> <p>The PET/CT images were acquired at 30 to 169 minutes (mean [SD], 76.5 [22.8]) after injection of 3.9 to 13.6 mCi (mean [SD], 7.3 [2.4]) of <sup>18</sup>F-NaF. The range and mean (SD) of SUVmax for <sup>18</sup>F-NaF–avid metastasis were 4.5 to 103.3 and 25.9 (16.6) and for <sup>18</sup>F-NaF–avid degenerative changes were 3.3 to 52.1 and 16.5 (7.9), respectively.</p> </sec> <sec> <title>Conclusions</title> <p>Various skeletal sites have different normal SUVs. Skeletal metastases have different SUVs when compared with benign findings such as degenerative changes.</p> </sec> </abstract>